A phase 2 clinical trial to investigate AR101 treatment with adjunctive dupilumab in patients with peanut allergies

Trial Profile

A phase 2 clinical trial to investigate AR101 treatment with adjunctive dupilumab in patients with peanut allergies

Planning
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs AR 101 (Primary) ; Dupilumab
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 19 Oct 2017 New trial record
    • 16 Oct 2017 This trial is expected to begin in 2018 according to an Aimmune Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top